Skip to Main Content

WASHINGTON — The maker of one of the world’s most profitable medicines is exiting the pharmaceutical industry’s two major lobbying organizations next year, just as Washington pledges to crack down on high drug costs.

AbbVie, which for years has fought off competition for its blockbuster autoimmune drug Humira — the world’s top-selling medicine before Pfizer’s Covid-19 vaccine hit the market — has been the target of congressional hearings and legislation aimed at so-called patent thickets that can stall rival products.


But now, AbbVie, which is, on its own, one of the top lobbying spenders in the pharmaceutical industry this year, is exiting both the Biotechnology Innovation Organization and the brand drug lobby PhRMA. AbbVie’s exit was first reported by Politico.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.